Key result
Cryoballoon ablation for atrial fibrillation showed similar safety across ages, but AF recurrences were more frequent in patients over 74 years (40.9% freedom from recurrence at 24 months).
Why the study?
The real-world efficacy and safety of AF ablation in particularly young and elderly patients remained under debate.
Does age affect the efficacy and safety of cryoballoon ablation in patients with paroxysmal or persistent drug-resistant and symptomatic atrial fibrillation?
Observational (n=2,534)
Yes
Does age affect the efficacy and safety of cryoballoon ablation in patients with paroxysmal or persistent drug-resistant and symptomatic atrial fibrillation?
Cryoballoon ablation for atrial fibrillation demonstrates a high degree of safety and comparable efficacy across age groups, though patients over 74 years may experience more frequent recurrences.
May inform age-stratified expectations for recurrence; leaves open whether randomized trials confirm differential efficacy by age.
BACKGROUND: The real-world efficacy and safety of atrial fibrillation (AF) ablation in particularly young and elderly patients are still under debate. The aim of the analysis was to investigate the effect of age on the efficacy and safety of cryoballoon ablation (CBA). METHODS: 2,534 patients underwent pulmonary vein isolation (PVI) by way of CBA for paroxysmal or persistent drug-resistant and symptomatic AF. The population was divided into age quartiles for evaluation, including (1) <53 years, (2) ≥53 and <61 years, (3) ≥61 and <67 years, and (4) ≥67 years. Furthermore, outcomes were analyzed in patients <41 years, ≥41 and ≤74, and >74 years old. Procedural data and complications were collected, and atrial fibrillation recurrences were evaluated during follow-up. RESULTS: =0.21), respectively (with increasing age). At 24-month follow-up, similar incidences of AF recurrence were observed in the four subgroups. When the sample was arbitrarily divided into the three age groups, a higher rate of recurrence was observed in older patients with regard to long-term follow-up (freedom from AF recurrence was 71.8% and 40.9%, respectively, at 12 and 24-month follow-up). In the univariate and multivariate analysis, age did not result in a significant predictor of AF recurrence during follow-up; however, a trend toward higher AF recurrences rates in patients ≥67 years was observed. CONCLUSION: The data demonstrated a high degree of safety during CBA across all patient ages. Procedural performance and complications were similar between different ages; AF recurrences seem to be more frequent in patients over 74 years.
No takes yet. Share an insight, caveat, or question.
Sciarra et al. (2021) conducted an observational in paroxysmal or persistent drug-resistant and symptomatic atrial fibrillation (n=2,534). Older age (>74 years) vs. Younger age groups was evaluated on Atrial fibrillation recurrence. Cryoballoon ablation for atrial fibrillation showed similar safety across ages, but AF recurrences were more frequent in patients over 74 years (40.9% freedom from recurrence at 24 months).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: